Key result
Multi-modality non-invasive CV screening linked to ~24% lower all-cause mortality vs no screening.
Why the study?
Cardiovascular screening reduces mortality in trials involving men, but its effect in both sexes remained to be evaluated.
Does multi-modality non-invasive cardiovascular screening reduce all-cause mortality in 67-year-old adults?
Cohort (n=21,648)
Does multi-modality non-invasive cardiovascular screening reduce all-cause mortality in 67-year-old adults?
Effect estimate: HR 0.76 (95% CI 0.68-0.85)
Absolute Event Rate: 6.9% vs 8.9%
p-value: p=<.001
Multi-modality cardiovascular screening in 67-year-olds significantly reduces all-cause mortality in both men and women, with the greatest benefit seen in those without prior cardiovascular disease.
Hypothesis-generating for mortality reduction via multi-modality CV screening; leaves open causality pending RCT confirmation.
BACKGROUND AND AIMS: Cardiovascular screening has been shown to reduce mortality in trials involving men. This study evaluated the effect of cardiovascular screening in both sexes, with all-cause mortality as the primary outcome. METHODS: The Viborg Screening Program, a prospective, population-based study in Denmark, in which the intervention consisted of inviting all 67-year olds to screening for carotid plaque, lower extremity artery disease, abdominal aortic aneurysm, hypertension, cardiac arrhythmia/ischaemia, and diabetes mellitus. This cohort included invitees from the first 5 years (2014-2019). Controls were 67-year olds without screening access. Effects were evaluated using propensity score matching (1:3 ratio, nearest-neighbour matching) and analysed using Cox proportional hazards models under the intention-to-invite principle. Sex-stratified analyses of all-cause mortality were conducted post hoc. RESULTS: Among 5505 invitees, three died before inclusion and 4602 participated (83.6%). Ninety individuals lacked registry information. After matching, 5412 invitees and 16 236 controls were included. During a median follow-up of 5.8 years, 372 (6.9%) invitees and 1444 (8.9%) controls died [hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.68-0.85; P < .001]. The number needed to invite to save one life was 49. The HR for cardiovascular mortality was 0.76 (95% CI 0.56-1.03), for major adverse cardiovascular events 1.10 (95% CI 1.01-1.19), and for major adverse limb events 0.70 (95% CI 0.50-0.98). All-cause mortality HRs were 0.73 (95% CI 0.63-0.84) for men, 0.82 (95% CI 0.68-0.98) for women, 0.70 (95% CI 0.61-0.80) for those without prior cardiovascular disease (CVD), and 0.97 (95% CI 0.78-1.21) for those with prior CVD. CONCLUSIONS: Multi-modality non-invasive cardiovascular screening reduced 5-year all-cause mortality among 67-year olds, also when stratified by sex. Prioritizing individuals without known CVD may enhance population-level impact.
No takes yet. Share an insight, caveat, or question.
Dahl et al. (2026) conducted a cohort in Cardiovascular disease risk (n=21,648). Multi-modality non-invasive cardiovascular screening vs. No screening access was evaluated on All-cause mortality (HR 0.76, 95% CI 0.68-0.85, p=<.001). Multi-modality non-invasive cardiovascular screening reduced all-cause mortality compared to no screening (6.9% vs 8.9%; HR 0.76; 95% CI 0.68-0.85; P<.001) over a median follow-up of 5.8 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: